<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00836056</url>
  </required_header>
  <id_info>
    <org_study_id>30312</org_study_id>
    <nct_id>NCT00836056</nct_id>
  </id_info>
  <brief_title>Clindamycin 300 mg Capsules in Healthy Subjects Under Fasting Conditions</brief_title>
  <official_title>Randomized, 2-Way Crossover, Bioequivalence Study of Clindamycin 300 mg Capsules and Cleocin HCl Administered as 1 x 300 mg Capsule in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the rate and extent of absorption of clindamycin&#xD;
      300 mg capsules (test) versus Cleocin HCl (reference), administered as 1 x 300 mg capsule&#xD;
      under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria&#xD;
&#xD;
      Statistical Methods: FDA bioequivalence statistical methods&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">November 2003</completion_date>
  <primary_completion_date type="Actual">November 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence Based on Cmax</measure>
    <time_frame>Blood samples collected over 24 hour period</time_frame>
    <description>Cmax - Maximum Observed Concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence Based on AUCinf</measure>
    <time_frame>Blood samples collected over 24 hour period</time_frame>
    <description>AUCinf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence Based on AUC0-t</measure>
    <time_frame>Blood samples collected over 24 hour period</time_frame>
    <description>AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Clindamycin (test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clindamycin 300 mg Capsule (test) dosed in first period followed by Cleocin® 300 mg Capsule (reference) dosed in second period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cleocin® (reference)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cleocin® 300 mg Capsule (reference) dosed in first period followed by Clindamycin 300 mg Capsule (test) dosed in second period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin 300 mg capsule</intervention_name>
    <description>1 x 300 mg</description>
    <arm_group_label>Clindamycin (test)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cleocin HCl 300 mg capsules</intervention_name>
    <description>1 x 300 mg</description>
    <arm_group_label>Cleocin® (reference)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Child-bearing potential or non-child-bearing potential female or male, non-smoker, ≥&#xD;
             18 and ≤65 years of age.&#xD;
&#xD;
          -  Non-child-bearing potential female subject is defined as follows:&#xD;
&#xD;
               1. Post-menopausal state: absence of menses for 12 months prior to drug&#xD;
                  administration or hysterectomy with bilateral oophorectomy at least 6 months&#xD;
                  prior to drug administration.&#xD;
&#xD;
               2. Surgically sterile: hysterectomy, bilateral oophorectomy, or tubal ligation at&#xD;
                  least 6 months prior to drug administration.&#xD;
&#xD;
          -  Capable of consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant illnesses within 4 weeks prior to the administration of the&#xD;
             study medication.&#xD;
&#xD;
          -  Clinically significant surgery within 4 weeks prior ot the administration of the study&#xD;
             medication.&#xD;
&#xD;
          -  Any clinically significant abnormality found during the medical screening.&#xD;
&#xD;
          -  Any reason which, in the opinion of the Medical Sub-Investigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
&#xD;
          -  Abnormal laboratory tests judged clinically significant.&#xD;
&#xD;
          -  Positive testing for hepatitis B, hepatitis C, or HIV at screening.&#xD;
&#xD;
          -  EGC abnormalities (clinically significant) or vital sign abnormalities(systolic blood&#xD;
             pressure lower than 90 over 140 mmHg, diastolic blood pressure lower than 50 or over&#xD;
             90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.&#xD;
&#xD;
          -  BMI≥ 30.0kg/m2.&#xD;
&#xD;
          -  History of significant alcohol abuse within six months prior to the screening visit or&#xD;
             any indication of the regular use of more than fourteen units of alcohol per week ( 1&#xD;
             Unit= 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol) or positive alcohol&#xD;
             breath test at screening.&#xD;
&#xD;
          -  History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana)&#xD;
             within 3 months prior to the screening visit or hard drugs (such as cocaine,&#xD;
             phencyclidine [PCP] and crack) within 1 year prior to the screening visit or positive&#xD;
             urine drug screen at screening.&#xD;
&#xD;
          -  History of allergic reactions to clindamycin or other related drugs (e.g. lienomycin).&#xD;
&#xD;
          -  History of allergic reactions to heparin.&#xD;
&#xD;
          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of&#xD;
             inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, rifampin/rifabutin;&#xD;
             examples of inhibitors: antidepressants, cimetidine, diltiazem, erythromycin,&#xD;
             ketoconazole, MAO inhibitors, neuroleptics, verapamil, quinidine) within 30 days prior&#xD;
             to administration of the study medication.&#xD;
&#xD;
        Use of an investigational drug or participation in an investigational study within 30 days&#xD;
        prior to administration of the study medication.&#xD;
&#xD;
          -  Clinically significant history or presence of any clinically significant&#xD;
             gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases),&#xD;
             unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney&#xD;
             disease, or other conditions known to interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of the drug.&#xD;
&#xD;
          -  Any clinically significant history or presence of clinically significant neurological,&#xD;
             endocrinal, cardiovascular, pulmonary, haematologic, immunologic, psychiatric, or&#xD;
             metabolic disease.&#xD;
&#xD;
          -  Use of prescription medication within 14 days prior to administration of study&#xD;
             medication or over-the-counter products ( including natural food supplements,&#xD;
             vitamins, garlic as supplement) within 7 days prior to administration of study&#xD;
             medication, except for topical products without systemic absorption.&#xD;
&#xD;
          -  Difficulty to swallow study medication.&#xD;
&#xD;
          -  Use of any tobacco products in the 90 days preceding drug administration.&#xD;
&#xD;
          -  Any food allergy, intolerance, restriction or special diet that could, in the opinion&#xD;
             of the Medical Subinvestigator, contraindicate the subjects's participation in this&#xD;
             study.&#xD;
&#xD;
          -  A depot injection or an implant of any drug within 3 months prior to administration of&#xD;
             study medication.&#xD;
&#xD;
          -  Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or&#xD;
             loss of whole blood prior to administration of the study medication as follows:&#xD;
&#xD;
               1. less than 300 mL or whole blood within 30 days,&#xD;
&#xD;
               2. 300 mL to 500 mL of whole blood within 45 days,&#xD;
&#xD;
               3. more than 500 mL of whole blood within 56 days prior to drug administration.&#xD;
&#xD;
          -  Intolerance to venipunctures.&#xD;
&#xD;
          -  Subjects with a clinically significant history of tuberculosis, epilepsy, asthma,&#xD;
             diabetes, psychosis, or glaucoma will not be eligible for this study.&#xD;
&#xD;
          -  Subjects unable to understand or unwilling to sign the Informed Consent Form.&#xD;
&#xD;
          -  Clinically significant history of diarrhea subsequent to administration or&#xD;
             antibacterial agents or antibiotics.&#xD;
&#xD;
          -  Additional exclusion criteria for females only:&#xD;
&#xD;
               1. Breast-feeding subject.&#xD;
&#xD;
               2. Positive urine pregnancy test at screening&#xD;
&#xD;
               3. Female subjects of childbearing potential having unprotected sexual intercourse&#xD;
                  with any non-sterile male partner (i.e. male who has not been sterilized by&#xD;
                  vasectomy for at least 6 months) within 14 says prior to study drug&#xD;
                  administration. Acceptable methods of contraception:&#xD;
&#xD;
                    1. condom + spermicide,&#xD;
&#xD;
                    2. diaphragm + spermicide,&#xD;
&#xD;
                    3. intra-uterine contraceptive devise (placed at least 4 weeks prior to study&#xD;
                       drug administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Girard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharn Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm Inc.</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>February 3, 2009</study_first_submitted>
  <study_first_submitted_qc>February 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2009</study_first_posted>
  <results_first_submitted>June 18, 2009</results_first_submitted>
  <results_first_submitted_qc>June 18, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2009</results_first_posted>
  <last_update_submitted>September 1, 2009</last_update_submitted>
  <last_update_submitted_qc>September 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2009</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Clindamycin (Test) First</title>
          <description>Clindamycin 300 mg Capsule (test) dosed in first period followed by Cleocin® 300 mg Capsule (reference) dosed in second period</description>
        </group>
        <group group_id="P2">
          <title>Cleocin® (Reference) First</title>
          <description>Cleocin® 300 mg Capsule (reference) dosed in first period followed by Clindamycin 300 mg Capsule (test) dosed in second period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout: 7 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clindamycin (Test) First</title>
          <description>Clindamycin 300 mg Capsule (test) dosed in first period followed by Cleocin® 300 mg Capsule (reference) dosed in second period</description>
        </group>
        <group group_id="B2">
          <title>Cleocin® (Reference) First</title>
          <description>Cleocin® 300 mg Capsule (reference) dosed in first period followed by Clindamycin 300 mg Capsule (test) dosed in second period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based on Cmax</title>
        <description>Cmax - Maximum Observed Concentration</description>
        <time_frame>Blood samples collected over 24 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Clindamycin</title>
            <description>Clindamycin 300 mg Capsule (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Cleocin®</title>
            <description>Cleocin® 300 mg Capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based on Cmax</title>
          <description>Cmax - Maximum Observed Concentration</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3008.88" spread="860.12"/>
                    <measurement group_id="O2" value="3086.02" spread="988.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, ANOVA (Analysis of Variance) will be performed on log-transformed AUC0-t, AUC0-inf and Cmax at the alpha level of 0.05.</non_inferiority_desc>
            <param_type>Test/Ref Ratio of LS Means x 100</param_type>
            <param_value>97.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>91.50</ci_lower_limit>
            <ci_upper_limit>104.42</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based on AUCinf</title>
        <description>AUCinf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
        <time_frame>Blood samples collected over 24 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Clindamycin</title>
            <description>Clindamycin 300 mg Capsule (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Cleocin®</title>
            <description>Cleocin® 300 mg Capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based on AUCinf</title>
          <description>AUCinf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10646.98" spread="3549.49"/>
                    <measurement group_id="O2" value="10890.41" spread="3297.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, ANOVA (Analysis of Variance) will be performed on log-transformed AUC0-t, AUC0-inf and Cmax at the alpha level of 0.05.</non_inferiority_desc>
            <param_type>Test/Ref Ratio of LS Means x 100</param_type>
            <param_value>96.77</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>91.40</ci_lower_limit>
            <ci_upper_limit>102.46</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based on AUC0-t</title>
        <description>AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration</description>
        <time_frame>Blood samples collected over 24 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Clindamycin</title>
            <description>Clindamycin 300 mg Capsule (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Cleocin®</title>
            <description>Cleocin® 300 mg Capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based on AUC0-t</title>
          <description>AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10218.56" spread="3500.68"/>
                    <measurement group_id="O2" value="10504.80" spread="3172.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, ANOVA (Analysis of Variance) will be performed on log-transformed AUC0-t, AUC0-inf and Cmax at the alpha level of 0.05.</non_inferiority_desc>
            <param_type>Test/Ref Ratio of LS Means x 100</param_type>
            <param_value>95.96</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>90.77</ci_lower_limit>
            <ci_upper_limit>101.46</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigator is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager, Biopharmaceutics</name_or_title>
      <organization>Teva Pharmaceuticals USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

